Liraglutide
SAXAPCOS
Novo Nordisk · Phase 3 · Completed · Enrollment 88
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
- Liraglutide Pen Injector (Saxenda): week 32 5.7%
- Placebo liraglutide pen injector: week 32 1.4%
One reported week is a point at that week. It is not a line from 0%. A solid line connects two or more reported weeks.